Literature DB >> 15573949

Acute retinal toxicity from the novel anti-tumor agent, Irofulven.

Robert F Melendez1, Joseph M Harrison, Eric K Rowinsky, Lisa A Hammond, Thomas D Fitzsimmons.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15573949     DOI： 10.1007/s10633-004-4085-2

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN： 0012-4486            Impact factor:   2.379


× No keyword cloud information.
  6 in total

1.  Clinical trials referral resource. Clinical trials of MGI-114.

Authors:  A Murgo; D J Cannon; G Blatner; B D Cheson
Journal:  Oncology (Williston Park)       Date:  1999-02       Impact factor: 2.990

2.  Antibiotic substances from Basidiomycetes+. VII. Clitocybe illudens.

Authors:  M ANCHEL; A HERVEY; W J ROBBINS
Journal:  Proc Natl Acad Sci U S A       Date:  1950-05       Impact factor: 11.205

3.  Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF).

Authors:  B A Woynarowska; J M Woynarowski; M C Herzig; K Roberts; A L Higdon; J R MacDonald
Journal:  Biochem Pharmacol       Date:  2000-05-15       Impact factor: 5.858

4.  A clinical triad to diagnose paraneoplastic retinopathy.

Authors:  D M Jacobson; C E Thirkill; S J Tipping
Journal:  Ann Neurol       Date:  1990-08       Impact factor: 10.422

5.  (Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties.

Authors:  T C McMorris; M J Kelner; W Wang; J Yu; L A Estes; R Taetle
Journal:  J Nat Prod       Date:  1996-09       Impact factor: 4.050

6.  Cancer-associated retinopathy.

Authors:  S M Goldstein; N A Syed; A H Milam; A M Maguire; T J Lawton; C W Nichols
Journal:  Arch Ophthalmol       Date:  1999-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.